The influence of different inositol stereoisomers supplementation in pregnancy on maternal gestational diabetes mellitus and fetal outcomes in high-risk patients: a randomized controlled trial

Inositol and antioxidant supplementation: Safety and efficacy in pregnancy

“…Women randomized to Myo also delivered at a longer gestational age, and less episodes of neonatal hypoglycaemia occurred in their offsprings. This was confirmed by a larger randomized controlled trial by Celentano et al who observed that Myo supplementation (2 g twice a day) in women at high risk for GDM reduced the incidence of diabetes as compared with DCI alone (500 mg) and also as compared with the association of Myo/DCI (1100 mg/27.6 mg).…”

“…On the contrary, in the study by Farren et al, in 240 pregnant women with a family history of diabetes, recruited between the 10th and 16th weeks of gestation, a lower fixed‐dosage combination of Myo/DCI/FA (1100 mg/27.6 mg/400 μg, respectively) did not result in any reduction in the incidence of GDM as compared with the treatment with FA only. As already mentioned, Celentano et al recently demonstrated the greatest benefit of Myo (4000 mg) compared with DCI alone (500 mg) and Myo/DCI association (1100 mg/27.6 mg) in the prevention of GDM in high‐risk pregnant women. These results, at odds with the previous study by Dell'Edera et al, could be due to either the use of inadequate doses of Myo/DCI or to late intervention …”

“…A strong body of evidences suggests that, if used early in the course of pregnancy in women at high risk for GDM, inositols are able to significantly reduce the incidence of glucose metabolism alterations during pregnancy . The use of these molecules in GDM is associated with improved glucose metabolism and reduced adverse foetal/neonatal outcomes.…”

“…Opposite data were obtained in a study comparing different inositol stereoisomers in GDM women where insulin sensitivity was not affected by treatment with 250 mg of DCI plus 200 μg FA, twice a day . In addition, in a randomized controlled trial, Celentano et al used different inositol stereoisomers in order to investigate their ability to prevent GDM in high‐risk women and obtained the largest benefit with Myo supplementation, as compared with supplementation with DCI or with Myo/DCI.…”

Mechanisms of Insulin Resistance Formation in Polycystic Ovarian Disease and Therapeutic Effects from Myo Inositol

“…В группах принимавших МИ и МИ + ДХИ потребовалась также меньшая доза инсулина во время беременности. В ряде исследований продемонстрировано, что применение во время беременности МИ в дозировке 4 г в сутки не вызывает побочных эффектов и не обладает тератогенным действием [51,52].…”